ALLO vs AMGN · rev $4.6M vs P/E 24, rev $10.05B
Allogene Therapeutics Inc (ALLO) versus Amgen Inc (AMGN) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Latest reported ALLO revenue for 2026-06-30 was $4.6M. Net income was -$85.3M. ALLO currently screens at market cap $258.1M.
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
ALLO currently screens at market cap $258.1M. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Not investment advice. Open the ALLO and AMGN stock pages for the full models.
Not investment advice.